	US 12,084,502 B2
	CD33-binding polypeptides and uses thereof
Kyle S. Jones, San Marcos, CA (US); William Crago, San Diego, CA (US); Angelica Sanabria, La Jolla, CA (US); Andrew Hollands, La Jolla, CA (US); Jacob Gano, Encinitas, CA (US); Milton Ma, La Jolla, CA (US); John C. Timmer, San Diego, CA (US); and Brendan P. Eckelman, Encinitas, CA (US)
Assigned to Inhibrx Biosciences, Inc., La Jolla, CA (US)
Filed by Inhibrx Biosciences, Inc., La Jolla, CA (US)
Filed on Dec. 16, 2022, as Appl. No. 18/067,504.
Application 18/067,504 is a division of application No. 16/864,480, filed on May 1, 2020, granted, now 11,560,428.
Claims priority of provisional application 62/844,359, filed on May 7, 2019.
Claims priority of provisional application 62/843,408, filed on May 4, 2019.
Prior Publication US 2023/0312716 A1, Oct. 5, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 47/55 (2017.01)

CPC C07K 16/2809 (2013.01) [A61K 47/55 (2017.08); C07K 16/2818 (2013.01); C07K 16/283 (2013.01); C07K 16/2851 (2013.01); A61K 45/06 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01)]

27 Claims

1. An isolated nucleic acid that encodes a polypeptide comprising at least one VHH domain that binds CD33, wherein at least one VHH domain that binds CD33 comprises:

a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 47; a CDR2 comprising the amino acid sequence of SEQ ID NO: 48; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 49;

b) a CDR1 comprising the amino acid sequence of SEQ ID NO: 7; a CDR2 comprising the amino acid sequence of SEQ ID NO: 8; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 9;

c) a CDR1 comprising the amino acid sequence of SEQ ID NO: 50; a CDR2 comprising the amino acid sequence of SEQ ID NO: 51; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 52;

d) a CDR1 comprising the amino acid sequence of SEQ ID NO: 56; a CDR2 comprising the amino acid sequence of SEQ ID NO: 54 or 57; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 58;

e) a CDR1 comprising the amino acid sequence of SEQ ID NO: 59; a CDR2 comprising the amino acid sequence of SEQ ID NO: 60; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 61;

f) a CDR1 comprising the amino acid sequence of SEQ ID NO: 23 or 62; a CDR2 comprising the amino acid sequence of SEQ ID NO: 63; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 64;

g) a CDR1 comprising the amino acid sequence of SEQ ID NO: 65; a CDR2 comprising the amino acid sequence of SEQ ID NO: 66; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 67;

h) a CDR1 comprising the amino acid sequence of SEQ ID NO: 68; a CDR2 comprising the amino acid sequence of SEQ ID NO: 69; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 70; or

i) a CDR1 comprising the amino acid sequence of SEQ ID NO: 71; a CDR2 comprising the amino acid sequence of SEQ ID NO: 72; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 73.